Moderna caps off busy week with $1.2B CytomX collab to better target mRNA therapies

Moderna clearly has no interest in taking a pre-JPM breather. In the week ahead of the conference, the mRNA giant has already announced its first-ever acquisition, organized a CEO interview with Fierce Biotech—and now signed a protein-focused partnership to better target its therapies.